Abbott's Q1 MDx Sales Rise 5 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Abbott today reported 3 percent first quarter growth for its diagnostics business including a 5 percent increase in year-over-year molecular diagnostics sales.

The firm reported overall diagnostics dales of $1.12 billion for the three months ended March 31, up from $1.09 billion for Q1 2013. On an operational basis, its diagnostics sales were up 5 percent. It said that the diagnostics business was hit by a 2.5 percent negative effect from foreign exchange.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.